0OB3.L - Valneva SE
| Previous close | 5.75 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 69,855 |
| Market cap | 5.209M |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksValneva (VALN) Stock Down 53% in the Past Year: Here's Why
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.
ZacksValneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
ZacksWhat Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock
Valneva SE Sponsored ADR (VALN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ZacksValneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
ZacksValneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.
ZacksWall Street Analysts See a 65% Upside in Valneva SE Sponsored ADR (VALN): Can the Stock Really Move This High?
The mean of analysts' price targets for Valneva SE Sponsored ADR (VALN) points to a 65.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksAll You Need to Know About Valneva SE Sponsored ADR (VALN) Rating Upgrade to Buy
Valneva SE Sponsored ADR (VALN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksValneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
Business WireValneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
SAINT-HERBLAIN, France & CAMBRIDGE, Mass., September 08, 2022--Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.
Business WirePfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
- Motley Fool
How Pfizer Plans to Unlock Another Mass-Market Vaccine
As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.
- Motley Fool
Why Dynavax Crushed the Market on Thursday
Biotech Dynavax Technologies (NASDAQ: DVAX) had a terrific Thursday on the stock market. Thursday morning, Valneva announced that the committee for medicinal products for human use (CHMP) advising the European Medicines Agency (EMA) has recommended the jab be granted marketing authorization as a primary shot for adults 18 to 50 years old. The next step is for the European Commission (EC) to review the CHMP's recommendation and make a decision.
ZacksValneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ZacksPfizer (PFE) to Buy 8.1% Stake in Lyme Disease Vaccine Partner
Pfizer (PFE) is set to acquire 8.1% stake in Valneva's stock. Valneva will use the cash from this investment to support its phase III study for VLA15.
- Motley Fool
The Shopify Split Is Just Days Away, but This Tiny Nasdaq Stock Is Soaring Right Now
The stock market has been on edge for months, and investors haven't gotten a lot of respite in the downdraft that has taken major market benchmarks lower enough to trigger official bear markets. S&P 500 (SNPINDEX: ^GSPC) futures had gained 69 points to 3,745, and Nasdaq Composite (NASDAQINDEX: ^IXIC) futures had picked up 218 points to 11,515. Shopify (NYSE: SHOP) is moving forward with a stock split in just over a week that has been in the works for a while now, and investors are hoping that the move will help the shares recover from a steep plunge from their recent highs.
- Motley Fool
Pfizer Buys Stake in French Lyme Disease Jab Partner
There is currently no available vaccine for Lyme disease, the tick-borne infection that, while rarely fatal, can leave patients with debilitating...
ReutersPfizer to buy 8.1 percent stake in French vaccines company Valneva
PARIS (Reuters) -U.S. healthcare giant Pfizer has agreed to invest 90.5 million euros ($95.24 million) to buy an 8.1% percent stake in French vaccines company, as the companies announced developments in their partnership to tackle the Lyme disease. Pfizer will buy the stake in Valneva, which is also working on its COVID-19 vaccine, at a price of 9.49 euros per share, via a reserved capital increase. Shares in Valneva rose sharply, surging by 14.5% in early session trading to 9.09 euros.
Business WireValneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
SAINT-HERBLAIN, France & NEW YORK, June 20, 2022--Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.
- Zacks
Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why
Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine program into jeopardy.
ZacksBiotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
ZacksValneva (VALN) Down on its COVID-19 Vaccine Update in Europe
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.